Endocrine Today Current Issue
The following articles appeared in the print edition of Endocrine Today.
Table of Contents
- Procedure evolution, data growth boost success of bariatric, metabolic surgery Jennifer R. Southall
-
- Benefits of gender-affirming HT outweigh risks for most transgender women Michael Monostra
- CGM ‘becoming standard of care’ in diabetes management, with or without insulin use Regina Schaffer
- Despite effective new therapies, osteoporosis remains undiagnosed, untreated Erin T. Welsh, MA
- Diabetes care and education needs to diversify Jill Rollet
- Diabetes may be ‘no longer equivalent to CVD’ as a CV risk factor Michael Monostra
- Earlier diabetes diagnosis linked to younger age at natural menopause Michael Monostra
- HbA1c less than 7% recommended in type 1 diabetes to avoid retinopathy, nephropathy Erin T. Welsh, MA
- High sensitivity observed for most molecular tests assessing malignancy of thyroid nodules Michael Monostra
-
- Masked hypertension ‘real phenomenon’ driving cardiometabolic risk Regina Schaffer
- Menopausal hormone therapy may protect against adhesive capsulitis Erin T. Welsh, MA
- ‘Mind-blowing’ weight loss with semaglutide extends to adolescents with obesity Michael Monostra
- Most adults with thyroid cancer on levothyroxine do not reach target TSH levels Michael Monostra
- Most transgender adolescents continue to use gender-affirming hormones in adulthood Michael Monostra
- Recognize, treat ‘pre-obesity’ to reduce cardiometabolic risk Regina Schaffer
- Spinal cord stimulation advances therapy for painful diabetic peripheral neuropathy Eric Grigsby, MD
- VIDEO: Management of type 2 diabetes no longer just a ‘glucose-centric approach’ Regina Schaffer; Juan P. Frias, MD
-
- FDA approves second interchangeable insulin glargine biosimilar for patients with diabetes
- FDA approves teplizumab to delay type 1 diabetes onset
- FDA grants breakthrough therapy designation to setmelanotide for hypothalamic obesity
- Glucagon/GLP-1 dual receptor agonist bests 1 mg semaglutide for weight loss: Phase 2 trial Michael Monostra
- New hormone-based therapies poised to expand obesity treatment options Michael Monostra
- Significant weight loss among patients with hypothalamic obesity seen with setmelanotide Erin T. Welsh, MA
- VIDEO: Menopause symptoms may be associated with later health risks Jill Rollet; Nanette Santoro, MD
- Should BMI or diabetes control determine who receives bariatric and metabolic surgery?
-